Met Non Small Cell Cancer Registry (MOMENT)

May 7, 2026 updated by: EMD Serono Research & Development Institute, Inc.

Disease Registry on Patients With Advanced NSCLC Harboring METex14 Skipping Alterations (MOMENT)

The purpose of this multi-national disease registry is to collect prospectively (with longitudinal follow-up) high-quality, standardized, and contemporaneous data to capture changes in the non-small cell lung cancer (NSCLC) treatment landscape and outcomes over time.

The registry will capture data on participants; demographic, clinical characteristics (including biomarker data), treatment patterns, and effectiveness and safety outcomes for advanced NSCLC with mesenchymal-epithelial transition exon 14(METex14) participants treated with systemic therapy.

Study Overview

Status

Recruiting

Conditions

Detailed Description

This is a disease registry, which is an organized system using non-interventional methods to collect data on a patient population defined by a particular disease, exposure, or condition, and which is followed over time. Non-interventional means that after participants enrollment, participants will be treated according to the routine clinical treatment decision by the physician. The registry will not impose any treatment or procedure for participants.

Study Type

Observational

Enrollment (Estimated)

700

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Austria
  • Belgium
  • Canada
      • Ottawa, Canada
        • Recruiting
        • Ottawa Hospital General Campus
        • Contact:
        • Principal Investigator:
          • Paul Wheatley-Price
      • Toronto, Canada
        • Recruiting
        • Princess Margaret Cancer Centre
        • Contact:
        • Principal Investigator:
          • Geoffrey Liu
  • Czechia
      • Olomouc, Czechia
      • Prague, Czechia
        • Recruiting
        • University Hospital Na Bulovce
        • Principal Investigator:
          • Petr Opalka
        • Contact:
  • France
      • Cholet, France
      • Lille, France
      • Lorient, France
        • Recruiting
        • Hôpital du Scorff
        • Contact:
        • Principal Investigator:
          • Régine Lamy
      • Lyon, France
      • Paris, France
        • Recruiting
        • Hospital Tenon & University Paris 6
        • Contact:
        • Principal Investigator:
          • Vincent Fallet
      • Paris, France
        • Recruiting
        • Institut Curie - Centre de Lutte Contre le Cancer (CLCC)
        • Principal Investigator:
          • nicolas girard
        • Contact:
      • Rennes, France, 35 033
      • Toulouse, France
  • Germany
  • Israel
      • Afula, Israel
        • Recruiting
        • Haemek Medical Center
        • Contact:
        • Principal Investigator:
          • Gil Bar-Sela
      • Haifa, Israel
      • Haifa, Israel
      • Haifa, Israel
      • Jerusalem, Israel
        • Recruiting
        • Shaare Zedek Medical Center
        • Principal Investigator:
          • Nir Peled
        • Contact:
      • Petah Tikva, Israel
        • Recruiting
        • Rabin Medical Center Oncology Beilinson Campus
        • Contact:
        • Principal Investigator:
          • Mor Moskovitz
      • Ramat Gan, Israel
      • Tel Aviv, Israel
        • Recruiting
        • Tel Aviv Sourasky Medical Center
        • Contact:
        • Principal Investigator:
          • Sivan Shamai
  • Italy
      • Milan, Italy
        • Recruiting
        • Istituto Europeo di Oncologia
        • Contact:
        • Principal Investigator:
          • Gianluca Spitaleri
      • Milan, Italy
      • Naples, Italy
        • Recruiting
        • AOU dell'Universita degli Studi della Campania Luigi Vanvitelli
        • Contact:
        • Principal Investigator:
          • Floriana Morgillo
      • Naples, Italy, 80131
        • Recruiting
        • Azienda Ospedaliera dei Colli - Ospedale Monaldi
        • Contact:
        • Principal Investigator:
          • Giuseppe Viscardi
      • Rome, Italy
        • Recruiting
        • I.F.O. Istituto Nazionale Tumori Regina Elena IRCCS
        • Contact:
        • Principal Investigator:
          • Gabriele Minuti
      • Torino, Italy
        • Recruiting
        • Azienda Sanitaria Ospedaliera S Luigi Gonzaga
        • Principal Investigator:
          • Silvia Novello
        • Contact:
      • Varese, Italy
  • Netherlands
      • Amsterdam, Netherlands
      • Groningen, Netherlands
        • Recruiting
        • Universitair Medisch Centrum Groningen - Department of Medical Oncology
        • Contact:
        • Principal Investigator:
          • Anthonie van der Wekken
      • Leiden, Netherlands
        • Recruiting
        • Leiden University Medical Center
        • Principal Investigator:
          • Egbert Smit
        • Contact:
  • Portugal
      • Lisbon, Portugal
        • Recruiting
        • Centro Hospitalar de Lisboa Norte, EPE - Hospital de Santa Maria
        • Contact:
        • Principal Investigator:
          • Andrea Machado
      • Porto, Portugal
      • Porto Covo, Portugal
  • Spain
      • Barcelona, Spain
        • Recruiting
        • Clinica Tres Torres
        • Contact:
        • Principal Investigator:
          • Santiago Viteri Ramirez
      • Barcelona, Spain
        • Terminated
        • Institut Universitari Dexeus-Quiron - Servei d oncologia medica - Institut Oncologic Dr. Rosell
      • Las Palmas de Gran Canaria, Spain
        • Terminated
        • Complejo Hospitalario Universitario Insular-Materno Infantil
      • Madrid, Spain
      • Madrid, Spain
        • Terminated
        • Centro Oncológico MD Anderson
      • Málaga, Spain
        • Recruiting
        • Hospital Regional Universitario de Malaga - Hospital General
        • Principal Investigator:
          • Manuel Cobo Dols
        • Contact:
      • Seville, Spain
        • Recruiting
        • Hospital Universitario Virgen Macarena
        • Principal Investigator:
          • David Vicente Baz
        • Contact:
      • Seville, Spain
        • Recruiting
        • Hospidal Universitario Ntra. Sra. De Valme
        • Principal Investigator:
          • Jose Fuentes Pradera
        • Contact:
      • Valencia, Spain
        • Recruiting
        • Hospital Universitari i Politecnic La Fe de Valencia
        • Contact:
        • Principal Investigator:
          • Francisco Aparisi
  • Sweden
  • United Kingdom
      • Bedford, United Kingdom
        • Recruiting
        • Bedford General Hospital
        • Contact:
        • Principal Investigator:
          • Venkata Bulusu
      • Birmingham, United Kingdom
        • Terminated
        • Birmingham Heartlands Hospital
      • Bournemouth, United Kingdom
        • Recruiting
        • Royal Bournemouth Hospital
        • Principal Investigator:
          • Tom Geldart
        • Contact:
      • Chelsea, United Kingdom
        • Recruiting
        • The Royal Marsden Hospital
        • Principal Investigator:
          • Sanjay Popat
        • Contact:
      • Harrow, United Kingdom
        • Recruiting
        • Northwick Park Hospital
        • Contact:
        • Principal Investigator:
          • Arshi Denton
      • Liverpool, United Kingdom
        • Recruiting
        • Clatterbridge Cancer Centre - Liverpool
        • Contact:
        • Principal Investigator:
          • Carles Escriu
      • London, United Kingdom, SE1 9RT
        • Not yet recruiting
        • Guy's Cancer Centre
        • Contact:
        • Principal Investigator:
          • Daniel Hughes
      • London, United Kingdom
        • Recruiting
        • Charing Cross Hospital
        • Contact:
        • Principal Investigator:
          • Joanne Evans
      • Preston, United Kingdom
        • Recruiting
        • Preston Hospital
        • Principal Investigator:
          • Pavel Bezecny
        • Contact:
    • West Yorkshire
      • Huddersfield, West Yorkshire, United Kingdom, HD3 3EA
        • Not yet recruiting
        • Huddersfield Royal Infirmary
        • Contact:
        • Principal Investigator:
          • Milly Finch
  • United States
    • Florida
      • Fort Lauderdale, Florida, United States, 33308-4603
        • Recruiting
        • Holy Cross Health
        • Contact:
        • Principal Investigator:
          • David Drew
    • Ohio
      • Columbus, Ohio, United States, 43221
        • Recruiting
        • The Ohio State University Wexner Medical Center
        • Contact:
        • Principal Investigator:
          • David Carbone
    • Tennessee
      • Nashville, Tennessee, United States, 37212
        • Active, not recruiting
        • Vanderbilt University Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Participants with advanced stage (stages IIIB-IV) NSCLC and confirmed METex14 skipping alterations who are initiating or already treated with a systemic therapy will be included.

Description

Inclusion Criteria:

  • Participants who signed ICF
  • Participants with advanced stage (stages IIIB-IV) NSCLC (all histologies) and Confirmed METex14 skipping alterations (by valid assay)
  • Participants who are starting or are already being treated with systemic therapy

Exclusion Criteria:

  • Participants who are enrolled in a clinical trial

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Other
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Advanced Non-small Cell Lung Cancer with METex14 skipping alterations
Participants diagnosed with advanced NSCLC and who receive available therapies in routine clinical practice setting will be part of this registry. Data will be collected routinely from the point of enrollment of a participants into the registry until death, loss to follow-up (drop-out), subsequent enrollment into a clinical trial, or end of data collection period for the registry.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Best Overall Response (BOR)
Time Frame: Through study completion, up to approximately 4.9 years
Through study completion, up to approximately 4.9 years
Tumor Response According to Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1
Time Frame: Up to approximately 4.9 years
Up to approximately 4.9 years
Overall Survival (OS)
Time Frame: Through study completion, up to approximately 4.9 years
Through study completion, up to approximately 4.9 years
Number of Participants with Adverse Events (AEs)
Time Frame: Up to approximately 4.9 years
Up to approximately 4.9 years
Number of Participants with Adverse Reactions (ARs)
Time Frame: Up to approximately 4.9 years
Up to approximately 4.9 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

EMD Serono Research & Development Institute, Inc.

Collaborators

Merck KGaA, Darmstadt, Germany

Investigators

  • Study Director: Medical Responsible, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 4, 2022

Primary Completion (Estimated)

April 28, 2028

Study Completion (Estimated)

April 28, 2028

Study Registration Dates

First Submitted

May 11, 2022

First Submitted That Met QC Criteria

May 11, 2022

First Posted (Actual)

May 17, 2022

Study Record Updates

Last Update Posted (Actual)

May 8, 2026

Last Update Submitted That Met QC Criteria

May 7, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • MS200095_0050

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cancer

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Singapore

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe